Technical Analysis for LCTX - Lineage Cell Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 1.0 -0.99% -0.01
LCTX closed down 0.99 percent on Tuesday, September 17, 2019, on 52 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical LCTX trend table...

Date Alert Name Type % Chg
Overbought Stochastic Strength 0.00%
Down 3 Days in a Row Weakness 0.00%
Stochastic Sell Signal Bearish -0.99%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.99%
Narrow Range Bar Range Contraction -0.99%
NR7 Range Contraction -0.99%
NR7-2 Range Contraction -0.99%
Weak + Overbought Other -0.99%
Weak, Overbought and Reversal Signs Reversal -0.99%
Overbought Stochastic Strength -0.99%

Older signals for LCTX ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy; ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis; and Premvia, a Hystem Hydrogel product, as well as develop bone grafting products for the orthopedic diseases and injuries. In addition, it markets GeneCards, a human gene database; MalaCards, a human disease database; and Hextend, a plasma volume expander used to treat or prevent hypovolemia, including albumin, generic 6% hetastarch solutions, and crystalloid solutions, as well as undertakes various research programs for vision restoration and Demyelination. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was founded in 1990 and is headquartered in Carlsbad, California.
Biotechnology Life Sciences Biology Immunotherapy Stem Cells Non Small Cell Lung Cancer Osteoarthritis Drug Delivery Cell Therapy Stem Cell Therapy Human Disease Injuries Biotime Degenerative Diseases Dry Age Related Macular Degeneration Renevia
Is LCTX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 2.63
52 Week Low 0.66
Average Volume 432,387
200-Day Moving Average 1.1593
50-Day Moving Average 1.0453
20-Day Moving Average 0.9678
10-Day Moving Average 0.9791
Average True Range 0.0717
ADX 17.28
+DI 15.0896
-DI 16.8924
Chandelier Exit (Long, 3 ATRs ) 0.8549
Chandelier Exit (Short, 3 ATRs ) 1.0351
Upper Bollinger Band 1.0771
Lower Bollinger Band 0.8585
Percent B (%b) 0.65
BandWidth 22.587311
MACD Line -0.0039
MACD Signal Line -0.0185
MACD Histogram 0.0146
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.06
Resistance 3 (R3) 1.06 1.05 1.05
Resistance 2 (R2) 1.05 1.03 1.05 1.05
Resistance 1 (R1) 1.02 1.02 1.02 1.02 1.04
Pivot Point 1.01 1.01 1.00 1.01 1.01
Support 1 (S1) 0.98 0.99 0.98 0.98 0.96
Support 2 (S2) 0.97 0.98 0.97 0.95
Support 3 (S3) 0.94 0.97 0.95
Support 4 (S4) 0.94